Trials / Completed
CompletedNCT01516892
A Long-term Efficacy, Safety, and Tolerability Study of BOTOX® in Patients With Chronic Migraine
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 716 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This open-label study will assess the long-term efficacy, safety, and tolerability of onabotulinumtoxinA administered for prophylaxis of headaches in patients with chronic migraine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | onabotulinumtoxinA | Participants received 155 U of onabotulinumtoxinA approximately every 12 weeks for 108 weeks. OnabotulinumtoxinA was administered as 31 intramuscular injections in 7 head/neck muscle areas. |
Timeline
- Start date
- 2011-12-01
- Primary completion
- 2015-11-01
- Completion
- 2015-11-01
- First posted
- 2012-01-25
- Last updated
- 2017-01-06
- Results posted
- 2017-01-06
Locations
32 sites across 3 countries: United States, Australia, South Korea
Source: ClinicalTrials.gov record NCT01516892. Inclusion in this directory is not an endorsement.